H3N2 HA Specific Neutra™ Antibody Products
Product listAre you facing challenges with H3N2 influenza virus antigenic drift, inconsistent neutralization assays, or a lack of high-affinity tools for functional studies? Creative Biolabs' H3N2 HA Specific Neutra™ Antibody Products overcome these hurdles through advanced antibody engineering and rigorous validation, empowering you to achieve precise, reliable results in antiviral research and therapeutic discovery.
Introduction to H3N2 Hemagglutinin (HA)
The hemagglutinin (HA) surface glycoprotein of Influenza A Virus Subtype H3N2 is the primary mediator of viral entry and a major target for neutralizing antibodies. Its continuous evolution poses significant challenges for vaccine design and therapeutic intervention. H3N2 HA is a trimeric class I fusion protein responsible for binding to sialic acid receptors on host respiratory epithelial cells and facilitating membrane fusion. As a dominant seasonal flu strain, H3N2 is notorious for its rapid antigenic drift.
- Structural Insights
The HA monomer comprises a globular head domain (HA1), containing the receptor-binding site and major antigenic sites, and a stem domain (HA2). Structural analyses, particularly via cryo-EM, reveal how mutations in the HA1 head, especially around antigenic sites A-E, drive immune escape while the more conserved stem region presents an attractive target for broadly neutralizing antibodies.
Fig.1 Structural basis of HA function and its distinct domains in H3N2.1
- Resistance and Signaling Pathways
Although H3N2 resistance mainly relies on neuraminidase inhibitors, mutations in hemagglutinin (HA) can modify receptor binding affinity and influence viral fitness. The binding of HA initiates endocytic pathways, and its fusion activity is contingent upon pH levels. The virus utilizes multiple strategies to evade host interferon responses, with HA indirectly contributing to the modulation of immune recognition.
H3N2 HA preferentially binds to α2,6-linked sialic acids, the human-type receptors. This attachment triggers clathrin-mediated endocytosis, activating the PI3K/Akt and Raf/MEK/ERK signaling cascades. These pathways are essential for endosomal acidification and subsequent membrane fusion. H3N2 HA also modulates the NF-κB pathway and induces caspase-dependent apoptosis in late stages of infection. Furthermore, HA-mediated signaling can suppress the interferon-beta (IFN-β) response, allowing the virus to replicate efficiently by evading the host's primary antiviral defenses.
- Clinical Impact
H3N2 is a major cause of seasonal influenza epidemics, associated with significant morbidity and mortality, particularly in high-risk groups like the elderly, young children, and immunocompromised individuals. It can lead to severe complications, including pneumonia, acute respiratory distress syndrome (ARDS), and exacerbation of underlying cardiopulmonary conditions.
-
Antibodies Against H3N2 HA
Neutralizing antibodies directed against H3N2 HA are essential for effective viral clearance. They mainly operate by preventing receptor binding or inhibiting the conformational alterations necessary for membrane fusion. High-quality anti-HA antibodies are critical for:- Tracking antigenic evolution and evaluating the compatibility of vaccine strains.
- Determining neutralizing antibody titers in sera (using HAI and MN assays).
- Developing therapeutic mAbs that target conserved epitopes.
- Investigating the structure-function relationships of HA and the mechanisms of fusion.
Applications of Anti-H3N2 HA Neutralizing Antibodies
Fig.2 Reactivity of antibodies against trimeric hemagglutinin (HA) of H3N2.2
- Vaccine Efficacy and Immunogenicity Assessment
Anti-H3N2 hemagglutinin (HA) neutralizing antibodies represent the benchmark correlate of protection in the development of influenza vaccines. They are utilized in hemagglutination inhibition (HI) and microneutralization (MN) assays to measure functional antibody responses in clinical trial samples following vaccination. Such data is essential for assessing vaccine immunogenicity, evaluating cross-reactivity against drifted strains, and guiding the annual selection of vaccine strains by global health organizations.
- Development of Broad-Spectrum Therapeutic Antibodies
mAbs targeting conserved epitopes in the HA stem region show promise as broad-spectrum therapeutics against H3N2 and other group 2 influenza viruses. These antibodies can protect against severe infection in preclinical models. In clinical settings, such mAbs are investigated for post-exposure prophylaxis and treatment, especially for immunocompromised patients, offering a strategy to mitigate disease severity and combat antigenic drift.
- Diagnostic and Surveillance Tool Development
High-specificity anti-H3N2 hemagglutinin antibodies serve as essential tools in rapid diagnostic tests (RDTs) and immunoassays aimed at virus identification. These antibodies facilitate the identification of distinct influenza subtypes, a crucial aspect for patient care and outbreak monitoring. Additionally, they play a role in the antigenic profiling of circulating viruses, enabling the tracking of evolutionary patterns and the identification of new variants that may pose pandemic risks.
Our Anti-H3N2 NA Specific Neutra™ Antibody Products
Creative Biolabs provides high-quality antibodies specifically designed for H3N2 research and development:
- Exceptional Specificity and Affinity: Our antibodies demonstrate outstanding specificity for H3N2 hemagglutinin, exhibiting minimal cross-reactivity with other influenza subtypes, which guarantees clear and interpretable results.
- Enhanced Neutralization Efficacy: Our Neutra™ antibodies have been validated through functional assays (such as microneutralization) and show robust virus-neutralizing capabilities.
- Targeting Conserved and Variable Epitopes: Our collection encompasses antibodies that recognize both the variable head domain (ideal for strain-specific investigations) and the conserved stem region (relevant for broad-neutralization studies).
- Thoroughly Validated: Every batch undergoes extensive validation for effectiveness in essential applications, including ELISA, Western Blot, Immunofluorescence, Hemagglutination Inhibition (HI), and neutralization assays.
- Reliable and Reproducible: Produced under strict quality control measures to ensure consistency across batches, supporting your long-term research endeavors.
Creative Biolabs is your trusted partner in virology research. We combine deep scientific knowledge with cutting-edge technology to provide research tools that you can rely on. Our H3N2 HA Specific Neutra™ Antibody Products are designed to accelerate your path from discovery to therapeutic and vaccine innovation. Contact our scientific team today to discuss your specific project requirements and request detailed product specifications.
References
- Bullard, Brianna L., and Eric A. Weaver. "Strategies targeting hemagglutinin as a universal influenza vaccine." Vaccines 9.3 (2021): 257. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/vaccines9030257
- Yoon, Aerin, et al. "An anti-influenza virus antibody inhibits viral infection by reducing nucleus entry of influenza nucleoprotein." PLoS One 10.10 (2015): e0141312. Distributed under Open Access license CC0, without modification. Doi: https://doi.org/10.3389/fimmu.2023.1323560
